MEK inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors

Mutant KRAS tumors are associated with poor outcomes at least in part due to decreased therapeutic sensitivity. Here we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with Poly-(ADP-ribose) polymerase inhibitors (PARPi) and immune checkpoint blockade w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Yang, Bin, Li, Xi, Fu, Yu, Guo, Ensong, Ye, Youqiong, Li, Fuxia, Liu, Si, Xiao, Rourou, Liu, Chen, Lu, Funian, Huang, Jia, Qin, Tianyu, Han, Leng, Peng, Guang, Mills, Gordon B., Sun, Chaoyang, Chen, Gang
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265237/
https://ncbi.nlm.nih.gov/pubmed/33589518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2370
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi